An exploratory, open-label, randomized Tria comparing Risperidone long-Acting Injectabl with oral antipsychotic medication in the treatment of early psychosis

Clinical Schizophrenia and Related Psychoses

Volumn 9, Issue 4, 2016, Pages 198-208

  Malla, Ashok ^a   Chue, Pierre ^a   Jordan, Gerald ^a,b   Stip, Emmanuel ^c   Koczerginski, David ^d,o   Milliken, Heather ^e   Joseph, Anil ^f   Williams, Richard ^g,l   Adams, Beverly ^h   Manchanda, Rahul ⁱ   Oyewumi, Kola ^j,m   Roy, Marc Andre ^k,n  

^a DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d William Osler Health Center   (Canada)

^e DALHOUSIE UNIVERSITY   (Canada)

^f Nova Scotia Early Psychosis Program   (Canada)

^g Health Sciences North ^*  (Canada)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ UNIVERSITY OF CALGARY   (Canada)

^j LONDON HEALTH SCIENCES CENTRE   (Canada)

^k QUEEN S UNIVERSITY   (Canada)

^l Southeastern Ontario District Early Intervention in Psychosis Program   (Canada)

^m CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

ⁿ UNIVERSITÉ LAVAL   (Canada)

^o CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

more..

Author keywords

Early Psychosis; RCT; Risperidone

Indexed keywords

OLANZAPINE; QUETIAPINE; RISPERIDONE; DELAYED RELEASE FORMULATION; NEUROLEPTIC AGENT;

ADULT; AKATHISIA; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXPLORATORY RESEARCH; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; LACERATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SIDE EFFECT; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; INJECTION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; OUTCOME ASSESSMENT; PSYCHOTIC DISORDERS;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA;

EID: 84966405084     PISSN: 19351232     EISSN: 19412010     Source Type: Journal    
DOI: 10.3371/CSRP.MACH.061213     Document Type: Article

References (42)

1. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991; 17(2):325-351.
2. Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. A randomized controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986; 148:120-127.
3. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011; 168(6):603-609.
4. Barkhof E, Meijer CJ, de Sonneville LM, Linszen DH, de Haan L. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia-A review of the past decade. Eur Psychiatry 2012; 27(1):9-18.
5. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002; 159(1):103-108.
6. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-Analysis. Lancet 2009; 373(9657):31-41.
7. Janssen: Risperidone powder for injectable prolonged-release suspension 12.5 mg, 25 mg, 37.5 mg, and 50 mg package insert. 2004.
8. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-Acting injectable risperidone: efficacy and safety of the first long-Acting atypical antipsychotic. Am J Psychiatry 2003; 160(6):1125-1132.
9. Thyssen A, Rusch S, Herben V, Quiroz J, Mannaert E. Risperidone long-Acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients. J Clin Pharmacol 2010; 50(9):1011-1021.
10. Zhornitsky S, Stip E. Oral versus long-Acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment non-Adherence: A systematic review. Schizophr Res Treatment 2012; 2012:407171.
11. Emsley R, Oosthuizen PP, Koen L, Niehaus DJ, Martinez G. Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: A 3-year open-label clinical study. J Clin Psychiatry 2012; 73(4):e541-547.
12. Canas F, Moller HJ. Long-Acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review. Expert Opin Drug Saf 2010; 9(5):683-697.
13. Knox ED, Stimmel GL. Clinical review of a long-Acting, injectable formulation of risperidone. Clin Ther 2004; 26(12):1994-2002.
14. Kissling W, Heres S, Lloyd K, Sacchetti E, Bouhours P, Medori R, et al. Direct transition to long-Acting risperidone-Analysis of long-Term efficacy. J Psycho-pharmacol 2005; 19(5 Suppl):15-21.
15. Lee SH, Choi TK, Suh S, Kim YW, Kim B, Lee E, et al. Effectiveness of a psycho-social intervention for relapse prevention in patients with schizophrenia receiving risperidone via long-Acting injection. Psychiatry Res 2010; 175(3):195-199.
16. Lasser RA, Bossie CA, Gharabawi GM, Kane JM. Remission in schizophrenia: Results from a 1-year study of long-Acting risperidone injection. Schizophr Res 2005; 77(2-3):215-227.
17. Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, et al. Comparative efficacy and safety of long-Acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005; 15(1):111-117.
18. Bai YM, Ting Chen T, Chen JY, Chang WH, Wu B, Hung CH, et al. Equivalent switching dose from oral risperidone to risperidone long-Acting injection: A 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry 2007; 68(8):1218-1225.
19. Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, et al. Long-Acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med 2011; 364(9):842-851.
20. Kim B, Lee SH, Choi TK, Suh S, Kim YW, Lee E, et al. Effectiveness of risperidone long-Acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(5):1231-1235.
21. Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfin-ger SM. A randomized controlled trial of long-Acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry 2009; 70(10):1397-1406.
22. Pandina G, Lane R, Gopal S, Gassmann-Mayer C, Hough D, Remmerie B, et al. A double-blind study of paliperidone palmitate and risperidone long-Acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35(1):218-226.
23. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997; 23(4):637-651.
24. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. J Clin Psychiatry 2002; 63(10):892-909.
25. Birchwood M, Spencer E. Early intervention in psychotic relapse. Clin Psychol Rev 2001; 21(8):1211-1226.
26. Gleeson J, EPISODE II Research Team. Preventing EPISODE II: relapse prevention in first-episode psychosis. Australas Psychiatry 2005; 13(4):384-387.
27. Guy W. ECDEU assessment manual for psychopharmacology. Rockville (MD): U.S. Department of Health, Education and Welfare; 1976.
28. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13(2):261-276.
29. Rush JJ. Handbook for psychiatric measures. Washington, DC, American Psychiatric Association, 2000.
30. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19.
31. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676.
32. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983; 13(1):177-183.
33. Csernansky JG, Mahmoud R, Brenner R; Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346(1):16-22.
34. Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J. Remission in patients with first-episode schizophrenia receiving assured anti-psychotic medication: A study with risperidone long-Acting injection. Int Clin Psychopharmacol 2008; 23(6):325-331.
35. Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chr-zanowski W, et al. Treatment of schizophrenia with long-Acting injectable ris-peridone: A 12-month open-label trial of the first long-Acting second-generation antipsychotic. J Clin Psychiatry 2003; 64(10):1250-1257.
36. Gefvert O, Eriksson B, Persson P, Helldin L, Bjorner A, Mannaert E, et al. Phar-macokinetics and D2 receptor occupancy of long-Acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharma-col 2005; 8(1):27-36.
37. Macfadden W, Bossie CA, Turkoz I, Haskins JT. Risperidone long-Acting therapy in stable patients with recently diagnosed schizophrenia. Int Clin Psycho-pharmacol 2010; 25(2):75-82.
38. Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, Fleis-chhacker WW, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998; 8(1):55-66.
39. Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa-McMillan A. Maintenance treatment with long-Acting injectable risperidone in first-episode schizophrenia: A randomized effectiveness study. J Clin Psychiatry 2012; 73(9):1224-1233.
40. Patel MX, Taylor M, David AS. Antipsychotic long-Acting injections: mind the gap. Br J Psychiatry Suppl 2009; 52:S1-4.
41. Heres S, Hamann J, Kissling W, Leucht S. Attitudes of psychiatrists toward anti-psychotic depot medication. J Clin Psychiatry 2006; 67(12):1948-1953.
42. Subotnik KL, Nuechterlein KH, Ventura J, Gitlin MJ, Marder S, Mintz J, et al. Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry 2011; 168(3):286-292.